Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2004
The proposed study is designed to test a novel dosing paradigm that would facilitate the treatment of anemia in CKD patients on dialysis. Anemic patients on hemo and peritoneal dialysis who have achieved and maintained target hemoglobin (Hb) on every other week (Q2W) dosing of darbepoetin alfa will have the dosing interval extended to once monthly (QM) dosing.
Epistemonikos ID: 73953d3b0af1f0f4bfb6b16481c3678c50240abd
First added on: May 04, 2024